Logo image of DVAX

DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis

NASDAQ:DVAX - Nasdaq - US2681582019 - Common Stock - Currency: USD

13.33  0 (0%)

After market: 13.33 0 (0%)

Fundamental Rating

5

Taking everything into account, DVAX scores 5 out of 10 in our fundamental rating. DVAX was compared to 572 industry peers in the Biotechnology industry. DVAX has only an average score on both its financial health and profitability. DVAX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

DVAX had positive earnings in the past year.
In the past year DVAX had a positive cash flow from operations.
In multiple years DVAX reported negative net income over the last 5 years.
In multiple years DVAX reported negative operating cash flow during the last 5 years.
DVAX Yearly Net Income VS EBIT VS OCF VS FCFDVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

1.2 Ratios

DVAX has a better Return On Assets (1.93%) than 93.43% of its industry peers.
DVAX's Return On Equity of 3.01% is amongst the best of the industry. DVAX outperforms 94.14% of its industry peers.
Industry RankSector Rank
ROA 1.93%
ROE 3.01%
ROIC N/A
ROA(3y)12%
ROA(5y)-8.23%
ROE(3y)27.27%
ROE(5y)-384.92%
ROIC(3y)N/A
ROIC(5y)N/A
DVAX Yearly ROA, ROE, ROICDVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

Looking at the Profit Margin, with a value of 7.85%, DVAX belongs to the top of the industry, outperforming 94.67% of the companies in the same industry.
Looking at the Gross Margin, with a value of 82.85%, DVAX belongs to the top of the industry, outperforming 87.74% of the companies in the same industry.
DVAX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 7.85%
GM 82.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
DVAX Yearly Profit, Operating, Gross MarginsDVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
DVAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DVAX Yearly Shares OutstandingDVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
DVAX Yearly Total Debt VS Total AssetsDVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 2.75 indicates that DVAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.75, DVAX is doing good in the industry, outperforming 73.53% of the companies in the same industry.
DVAX has a debt to FCF ratio of 9.85. This is a negative value and a sign of low solvency as DVAX would need 9.85 years to pay back of all of its debts.
The Debt to FCF ratio of DVAX (9.85) is better than 93.07% of its industry peers.
DVAX has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.33, DVAX is doing worse than 72.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF 9.85
Altman-Z 2.75
ROIC/WACCN/A
WACC9.05%
DVAX Yearly LT Debt VS Equity VS FCFDVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 13.23 indicates that DVAX has no problem at all paying its short term obligations.
DVAX's Current ratio of 13.23 is amongst the best of the industry. DVAX outperforms 85.97% of its industry peers.
A Quick Ratio of 12.34 indicates that DVAX has no problem at all paying its short term obligations.
DVAX has a better Quick ratio (12.34) than 84.55% of its industry peers.
Industry RankSector Rank
Current Ratio 13.23
Quick Ratio 12.34
DVAX Yearly Current Assets VS Current LiabilitesDVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

DVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 400.00%, which is quite impressive.
Measured over the past years, DVAX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.10% on average per year.
EPS 1Y (TTM)400%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.56%

3.2 Future

DVAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.59% yearly.
Based on estimates for the next years, DVAX will show a quite strong growth in Revenue. The Revenue will grow by 18.89% on average per year.
EPS Next Y46.01%
EPS Next 2Y63.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.6%
Revenue Next 2Y17.51%
Revenue Next 3Y20.35%
Revenue Next 5Y18.89%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
DVAX Yearly Revenue VS EstimatesDVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
DVAX Yearly EPS VS EstimatesDVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2 -3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 74.06, DVAX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, DVAX is valued cheaper than 93.43% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.63. DVAX is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 50.72 indicates a quite expensive valuation of DVAX.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaper than 91.65% of the companies in the same industry.
DVAX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 74.06
Fwd PE 50.72
DVAX Price Earnings VS Forward Price EarningsDVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, DVAX is valued cheaper than 93.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 77.24
EV/EBITDA N/A
DVAX Per share dataDVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

DVAX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
DVAX's earnings are expected to grow with 63.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y63.59%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYNAVAX TECHNOLOGIES CORP

NASDAQ:DVAX (2/21/2025, 8:14:41 PM)

After market: 13.33 0 (0%)

13.33

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners101.49%
Inst Owner Change-91.71%
Ins Owners0.33%
Ins Owner Change0.63%
Market Cap1.75B
Analysts81.67
Price Target24.07 (80.57%)
Short Float %14.84%
Short Ratio11.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.49%
Min EPS beat(2)3.56%
Max EPS beat(2)21.41%
EPS beat(4)3
Avg EPS beat(4)-20.01%
Min EPS beat(4)-205.01%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)96.03%
EPS beat(12)8
Avg EPS beat(12)88.23%
EPS beat(16)11
Avg EPS beat(16)49.38%
Revenue beat(2)0
Avg Revenue beat(2)-5.51%
Min Revenue beat(2)-6.08%
Max Revenue beat(2)-4.93%
Revenue beat(4)1
Avg Revenue beat(4)-4.27%
Min Revenue beat(4)-9.42%
Max Revenue beat(4)3.38%
Revenue beat(8)5
Avg Revenue beat(8)4.75%
Revenue beat(12)7
Avg Revenue beat(12)5.97%
Revenue beat(16)11
Avg Revenue beat(16)16.49%
PT rev (1m)-0.84%
PT rev (3m)-0.84%
EPS NQ rev (1m)10.53%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)2.64%
EPS NY rev (3m)-42.58%
Revenue NQ rev (1m)1.38%
Revenue NQ rev (3m)1.38%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.88%
Valuation
Industry RankSector Rank
PE 74.06
Fwd PE 50.72
P/S 6.72
P/FCF 77.24
P/OCF 64.27
P/B 2.57
P/tB 2.58
EV/EBITDA N/A
EPS(TTM)0.18
EY1.35%
EPS(NY)0.26
Fwd EY1.97%
FCF(TTM)0.17
FCFY1.29%
OCF(TTM)0.21
OCFY1.56%
SpS1.98
BVpS5.18
TBVpS5.17
PEG (NY)1.61
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.93%
ROE 3.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 7.85%
GM 82.85%
FCFM 8.7%
ROA(3y)12%
ROA(5y)-8.23%
ROE(3y)27.27%
ROE(5y)-384.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF 9.85
Debt/EBITDA N/A
Cap/Depr 99.85%
Cap/Sales 1.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 110.78%
Current Ratio 13.23
Quick Ratio 12.34
Altman-Z 2.75
F-Score5
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)167.43%
Cap/Depr(5y)165.59%
Cap/Sales(3y)1.64%
Cap/Sales(5y)22.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y46.01%
EPS Next 2Y63.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.56%
Revenue Next Year19.6%
Revenue Next 2Y17.51%
Revenue Next 3Y20.35%
Revenue Next 5Y18.89%
EBIT growth 1Y-120.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.66%
EBIT Next 3Y45.38%
EBIT Next 5YN/A
FCF growth 1Y-83.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.62%
OCF growth 3YN/A
OCF growth 5YN/A